Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect

Gynecologic Oncology

Volumn 73, Issue 2, 1999, Pages 280-284

  Silver, David F ^a   Piver, M Steven ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; Erythropoietin; Hematocrit; Ovarian cancer; Oxygen effect; Solid tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; GYNECOLOGIC CANCER; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032961222     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5368     Document Type: Article

References (16)

1. Cancer Facts and Figures - 1995, Atlanta, GA, Am Cancer Soc, 1995
2. Herman TS, Teicher BA, Collins LS: Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures. Cancer Res 48:2342-2347, 1988
3. Melvic JE, Pettersen EO: Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro. Radiat Res 114:489-499, 1988
4. Grau C, Overgaard J: Effects of cancer chemotherapy on the hypoxic fraction of solid tumor measured using a local tumor control assay. Radiother Oncol 13:301-309, 1988
5. Hollcroft JW, Lorenz E, Matthews M: Factors modifying the effect of x-irradiation on regression of a transplanted lymphosarcoma. J Natl Cancer Inst 12:751-763, 1952
6. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA: The concentration of oxygen dissolved in tissue at the time of irradiation as a factor of radiotherapy. Br J Radiol 26:638-648, 1953
7. Brown JM: Sensitizers and protectors in radiotherapy. Cancer 55:2222-2228, 1985
8. Bush RS, Jenkin RDT, Allt WEC, Beale FA, Bean H, Dembo AJ, Pringle JF: Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37:302-306, 1978
9. Xu Y, Silver DF, Yang NP, Rencuzogullari E, Hempling RE, Piver MS, Repasky EA: Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol, in press
10. Sakakibara T, Xu Y, Bumpers HL, Chen FA, Bankert RB, Arredondo MA, Edge SB, Repasky EA: Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. Cancer J Sci Am 2:291-300, 1996
11. Markman M: Current status and future directions of platinum/paclitaxel-based chemotherapy for ovarian cancer. Semin Oncol 24:S11-24-S11-27, 1997
12. Ozols RF, Vermorken JB: Chemotherapy of advanced ovarian cancer: Current status and future directions. Semin Oncol 24:S2-1-S2-9, 1997
13. Tonetti M, Gasparini A, Giovine M, Bini D, Mazzuccotelli A, DePaz F, Benatti U, DeFlora A: Interaction of carboplatin with carrier human erythrocytes. Biotechnol Appl Biochem 15:267-277, 1992
14. Tonetti M, Gasparini A, Giovine M, Benatti U, DeFlora A: Enhanced intracellular activation of carboplatin in hemaglobin-synthesizing versus undifferentiated erythroleukemic cells. Biochem Biophys Res Commun 182:760-766, 1992
15. Tonetti M, Giovine M, Gasparini A, Benatti U, DeFlora A: Enhanced formation of reactive species from cis-diamine-(1,1-cyclobutanedicarboxylato)-platinum(II) (carboplatin) in the presence of oxygen free radicals. Biochem Pharmacol 46:1377-1383, 1993
16. Kelleher DK, Matthiensen U, Thews O, Vaupel P: Blood flow, oxygenation and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 56:4728-4734, 1996